Cocolin

Quick links to important sections

Cocolin

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cocolin

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Oral preparations (syrup, solution, tablet)
Pharmacological class Antitussive (Cough suppressant)
Common use Symptomatic relief of dry, non-productive cough
Origin Synthetic, Morphinan derivative

Defining Cocolin: Classification and Active Ingredient

Cocolin is a pharmaceutical preparation classified as a centrally acting antitussive, or cough suppressant, containing Dextromethorphan Hydrobromide as the single active ingredient. Pharmacological studies describe this compound as a synthetic substance and a morphinan derivative, utilized for its ability to suppress the cough reflex. Crucially, Cocolin's profile distinguishes it as a non-opioid antitussive, meaning its cough-suppressing action is achieved without relying on the traditional opioid receptor pathway.

Dextromethorphan is intended to provide temporary relief of cough caused by minor throat and bronchial irritation. In this capacity, Cocolin's primary function is to offer temporary, targeted relief by directly influencing the medullary cough center in the brainstem, thereby elevating the cough reflex threshold.

The Composition and Purpose of Cocolin

Cocolin is an oral preparation, administered via the oral route of administration, and is typically marketed as a syrup, solution, or tablet, contained within an appropriate pharmaceutical base. The composition is that of a single-ingredient product, which directs the medication's effect exclusively toward managing the cough reflex.

The intended therapeutic function of this formulation is to reduce the frequency and intensity of a persistent, non-productive cough, commonly known as a dry cough. For instance, a typical use scenario involves calming the irritating cough that disrupts sleep or rest. Dextromethorphan is used in the management of dry coughs, which reflects the medication’s focused role in easing the disruptive symptom of dry, irritating coughing.

Regulatory References

  1. MedlinePlus: Dextromethorphan

What side effects are possible with Cocolin?

Possible Side Effects and Safety Information

Safety information for Cocolin (Dextromethorphan Hydrobromide) is structured by regulatory bodies, classifying potential effects based on physiological systems and documented frequency. Officially classified adverse reactions may include dizziness, nausea, vomiting, and general gastrointestinal disturbance, which are typically designated as uncommon [HPRA SmPC].

Adverse reactions are grouped by System Organ Class, involving the Nervous System (e.g., drowsiness, somnolence) and Psychiatric Disorders (e.g., agitation, confusional state) [National Drug Information (FDA MOPH)]. Additionally, the risk of drug dependence is noted in regulatory documents, correlating with exposure [FDA Verification Portal].

Serious Safety Concerns and Restrictions

The most serious risk documented in official safety summaries is the potential for Serotonin Syndrome, a severe reaction associated primarily with the concomitant use of other serotonergic agents, such as Monoamine Oxidase Inhibitors (MAOIs). Use is explicitly contraindicated with MAOIs [EFDA SmPC]. Further, the label advises against use in patients who are in, or at high risk of developing, respiratory failure [National Drug Information (FDA MOPH)].

Safety considerations are also defined for specific populations. Due to its metabolism and elimination, caution is advised and dose modification may be necessary for patients with hepatic impairment (liver problems) or renal impairment (kidney problems) [FDA Verification Portal]. Because of the potential for drowsiness, official safety notes indicate the medicine may impair cognitive function, which can affect the ability to drive or operate machinery [EFDA SmPC].

Overdose and Emergency Response

The official regulatory profile for Cocolin (Dextromethorphan Hydrobromide) overdose documents specific manifestations that indicate an acute toxic state. Overdose may present with severe central nervous system (CNS) effects, including confusion, agitation, hallucinations, and drowsiness, potentially progressing to coma or seizures. Neurological signs such as ataxia (loss of coordination) and involuntary eye movements (nystagmus) are also documented.

Severe systemic and cardiorespiratory compromise are officially noted complications. These include rapid heart rate (tachycardia), elevated blood pressure, and life-threatening respiratory depression or apnea, which is noted to be especially hazardous in young children. Officially documented severe outcomes also include hyperthermia and the potential development of Serotonin Syndrome.

Emergency Actions Mandated by Regulators

Seek immediate medical help right away for any suspected overdose. Emergency services must be contacted immediately if the affected individual has collapsed, experienced a seizure, is having significant trouble breathing, or cannot be awakened. This urgency is required due to the risk of severe outcomes.

Treatment is characterized as symptomatic and supportive care. Regulatory guidance confirms that no specific antidote exists for Dextromethorphan toxicity, though Naloxone may be considered for respiratory depression. Procedures such as administration of activated charcoal and monitoring of vital signs (ECG, blood pressure) are documented management steps.

Therapeutic Uses of Cocolin

What Cocolin Treats: Main Uses and Benefits

Cocolin (Dextromethorphan Hydrobromide) is applied in contexts where short-term supportive relief is needed to address symptomatic distress, focusing exclusively on certain acute respiratory manifestations. This medication is intended for the temporary relief of cough caused by the common cold, the flu, or other conditions.

It is commonly used across conditions presenting with acute or episodic changes characterized by periods of heightened symptoms that interfere with daily functioning. Cocolin is primarily relevant for easing symptoms related to inflammatory or irritative states that manifest as an irritating dry cough or a non-productive cough. This approach helps address symptom clusters that may become intense or disruptive.

The medication is utilized in situations requiring additional symptomatic assistance, often applied when symptoms become momentarily overwhelming. By addressing the persistent cough patterns, Cocolin contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability. The primary benefit is moderating disruptive symptoms to support the patient's ability to achieve rest.

“This medication is relevant when supportive symptom management is appropriate to ease the overall symptom load.”

Quick Fact: Common application in the management of irritating non-productive cough

Regulatory References

  1. NIH MedlinePlus overview of Dextromethorphan

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

The eligibility profile for Cocolin (Dextromethorphan Hydrobromide) is strictly defined by regulatory authorities to ensure safe use, primarily addressing age, existing medical conditions, and concurrent medication.

Absolute Contraindications

Cocolin must not be used by the following populations:

  • Patients taking, or who have taken, a Monoamine Oxidase Inhibitor (MAOI) within the preceding 14 days due to the severe risk of serotonin syndrome.
  • Individuals with known hypersensitivity to Dextromethorphan or any component in the formulation.
  • Patients experiencing or at risk of respiratory failure (e.g., during an acute asthma exacerbation).

Age-Based Mandates

Age Group Regulatory Status
Adults and Adolescents (≥12 years) Standard Use Population as per labeling.
Children under 12 years Often Contraindicated in European-style labeling.
Children under 4 years Not Recommended for non-prescription use (US guidance).

Conditional Use and Restrictions

Use of Cocolin requires caution or clinical oversight in patients with hepatic or renal impairment due to the drug’s metabolism. It is restricted to non-productive coughs only; it should not be used for coughs accompanied by excessive phlegm. Furthermore, use is not established as safe during pregnancy or lactation and is recommended only when deemed essential by a healthcare provider.

What should I know about interactions with other medicines?

The official regulatory profile for Cocolin (Dextromethorphan Hydrobromide) establishes specific restrictions regarding co-administration with other medicines and products.

Formal Contraindications and Administration Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. A mandatory restriction states that Cocolin must not be used in any patient who has taken an MAOI within the preceding 14 days.

Documented Interaction Patterns

Cocolin is primarily metabolized by the CYP2D6 enzyme. Co-administration with potent CYP2D6 Inhibitors (such as quinidine, fluoxetine, and paroxetine) results in a pharmacokinetic interaction. This interaction officially increases the concentration of Dextromethorphan in the plasma, which raises the risk of toxic effects.

A pharmacodynamic interaction exists with other serotonergic agents (e.g., SSRIs and SNRIs), as the combination results in additive serotonergic activity and a formal risk of Serotonin Syndrome. Additive Central Nervous System (CNS) depressant effects are also documented with substances like alcohol, narcotic analgesics, and tranquilizers. Furthermore, the label notes potential interactions with certain non-medicinal substances, including Grapefruit juice and the herbal product St. John's wort, which can lead to increased drug exposure.

Population-Specific Notes

Interaction potential is noted to be more significant in individuals identified as CYP2D6 Poor Metabolizers and those with hepatic impairment, a cautionary constraint noted in official prescribing information.

Mechanism of Action

Cocolin's active mechanism is exclusively central, occurring within the brainstem at the medullary cough center, the site that integrates the cough reflex. The drug acts as a primary agonist at the Sigma-1 (sigma1) receptor, which modulates calcium signaling and helps stabilize the activity of the surrounding neurons. This molecular action directly depresses the neuronal sensitivity within the center.

A secondary action involves the parent drug and its metabolite, Dextrorphan, functioning as non-competitive antagonists at the N-methyl-D-aspartate (NMDA) receptor. By reducing the excitatory input to the brainstem neurons through this channel blockade, the mechanism contributes to the overall reduction in excitability of the cough center. The resulting physiological consequence is an elevation of the cough reflex threshold, which requires a stronger afferent signal to generate the efferent motor command. This mechanism is characterized by targeted reflex dampening and exerts no action on the peripheral respiratory system or the production of mucus.

Dosage and Administration Information

Cocolin, which contains Dextromethorphan Hydrobromide, is administered exclusively via the oral route. The medication is available in various forms, including immediate-release (IR) liquids, syrups, and tablets, as well as extended-release (ER) oral suspensions.

Official Dosing and Frequency

Standard clinical profiles establish specific dosing ranges and intervals that are dependent on the product type. The use of Cocolin is intended to be as needed for symptoms.

Product Type Standard Adult Dose Frequency Pattern Maximum Daily Dose (24 h)
Immediate-Release (IR) 10 mg to 20 mg per administration Every 4 hours, or 30 mg every 6 to 8 hours 120 mg
Extended-Release (ER) 60 mg per administration Every 12 hours 120 mg

All doses must be measured accurately to prevent administration errors. For liquid and syrup forms, the product must be shaken well prior to measurement, and an accurate dosing device should be used instead of a household spoon. Cocolin may be taken with or without food.

Use Duration and Specific Populations

Cocolin is strictly intended for short-term use and is not indicated for administration over extended periods. Usage should generally not exceed 7 days. If a dose is missed, standard practice is to avoid taking a double dose; the patient should resume the next scheduled dose as planned.

Use in pediatric patients follows specific age criteria. Cocolin is not recommended for children under 4 years of age. Patients 12 years and older use the adult regimen, while individuals aged 4 to under 12 years require lower, age-based dosing schedules.

Recent Clinical Evidence

Research evidence / Overview of studies for Cocolin

This overview summarizes the structure and reported findings of official research for Cocolin (Dextromethorphan Hydrobromide), focusing on what studies have explored and where the evidence remains incomplete. This information is based on scientific reviews and regulatory documents and is not medical advice.


Evidence for Symptomatic Relief of Acute Dry Cough

Research has studied Cocolin for its relevance in trials assessing short-term or episodic symptom patterns related to a dry, non-productive cough, often triggered by minor irritation or the common cold. The main body of evidence consists of short-term, randomized controlled trials (RCTs) and scientific meta-analyses that have examined outcomes related to physical discomfort and daily functioning or activity level.

These studies were applied in research contexts involving fluctuating or unstable symptoms in typically healthy adults. Researchers primarily monitored patient-reported outcomes describing perceived discomfort and used objective tools to measure total cough counts and cough frequency.

The research highlights that findings were mixed across the various trials. Some studies reported a measured change in cough parameters during the observation period. However, other trials found that data show patterns related to only a very small difference when comparing Cocolin to non-active treatments (placebo). The overall evidence is limited and heterogeneous, meaning a fully consistent picture regarding the magnitude of any effect remains uncertain.


Research Gaps and Scientific Uncertainty

Official reviews consistently note that the research surrounding Cocolin has several key limitations. The evidence quality varies across studies, and the findings have been mixed, meaning that the certainty remains low regarding the magnitude and consistency of the measured effect.

A key gap is the methodological variability in how researchers measure cough. Both objective and subjective measurements were observed in research, and the lack of standardization across trials contributes to the difficulty in drawing firm conclusions. Long-term effects are not fully established, and data for certain groups remain insufficient, including for older adults.

Key Studies & References

  1. Dextromethorphan: MedlinePlus Drug Information (NIH)

Frequently Asked Questions (FAQ)

Common questions about Cocolin (FAQ)


Q: What Cocolin is used for besides the main condition?

Regulatory documents define the official purpose of this medication as the temporary relief of a dry, non-productive cough caused by minor throat and bronchial irritation. Official labeling restricts its use to this specific symptomatic relief. It is not indicated for any other medical conditions or uses.


Q: If I miss a dose of Cocolin, will it cause problems?

Regulatory information advises against taking a double dose if one is missed, and instructs patients to simply resume the next scheduled dose as planned. For short-term use, a single missed dose is not typically associated with immediate health problems. This information is intended to complement, not replace, the instructions provided by a healthcare professional.


Q: What should I do if I think Cocolin is not working?

Studies and official information indicate that if the cough does not improve within 7 days of starting the medication, or if the cough worsens, the regulatory guidance is to consult with a healthcare professional. This is based on the short-term intended use of the drug.


Q: What happens if I suddenly stop taking Cocolin?

Official documents note a risk of drug dependence associated with the use of the medication, primarily related to long-term or high-dose exposure. For short-term use at recommended doses, there are no specific regulatory warnings regarding immediate severe symptoms upon cessation.


Q: Can Cocolin cause changes in mood or behavior?

Yes, adverse reactions listed in regulatory safety summaries include psychiatric disorders such as agitation and a confusional state. Changes in mood or behavior have been reported, particularly with exposure to high doses. If concerning changes are observed, consulting a healthcare provider is noted as appropriate.


Q: What is the difference between Cocolin and its metabolite?

The active ingredient in the medication is processed by the liver into a chemical known as Dextrorphan, which is the primary metabolite. Both the original drug and this metabolite act on specific brain receptors to help reduce the cough reflex. This metabolite acts on specific brain receptors and contributes to the overall effect by helping to reduce the cough reflex.


Q: Does Cocolin interact with common painkillers like acetaminophen?

Regulatory drug interaction databases and safety summaries generally indicate no formal, clinically significant interaction between the active ingredient (Dextromethorphan) and acetaminophen.


Q: Why do official documents mention potential liver enzyme changes with Cocolin?

The medication's active ingredient is primarily processed in the liver by a specific enzyme (CYP2D6). Caution is advised because problems with the liver's ability to process the drug can lead to higher concentrations of the medication in the body, which can increase the risk of high concentrations of the medication in the body.


Q: Is there a generic version of Cocolin available yet?

The active ingredient in this medication is Dextromethorphan Hydrobromide, which is the generic drug. This compound is widely available and contained in many different over-the-counter products.


Q: Can Cocolin be taken with multivitamin supplements?

Official drug interaction listings generally indicate that there is no known, clinically significant interaction between the active ingredient and standard multivitamin supplements.


Q: Is Cocolin known to cause any skin reactions?

Officially classified side effects do not commonly include mild skin reactions. However, severe allergic reactions (known as hypersensitivity) to the medication's components are a formal contraindication in regulatory documents.


Q: Can Cocolin affect sleep patterns or cause insomnia?

Drowsiness and somnolence (sleepiness) are documented side effects due to the drug's central nervous system action. While the drug is a depressant, sleep disturbances such as insomnia have been reported, particularly in cases of increased exposure or overdose.


Q: What is the current status of research into Cocolin's long-term effects?

Official regulatory overviews state that research into the long-term effects of the medication is limited, and these effects are not fully established based on the current body of evidence.


Q: Are there specific symptoms that require immediate medical attention while taking Cocolin?

Regulatory safety documents list the symptoms of the rare but severe condition called Serotonin Syndrome. These symptoms may include changes in mental status, high blood pressure (hypertension), restlessness, increased reflexes, sweating, shivering, and tremor.


Q: How is Cocolin eliminated from the body?

After being processed in the liver (metabolism), the medication and its metabolites are primarily eliminated from the body through excretion in the urine. This is the body's natural process for removing the drug.


Q: Why are people often confused about the purpose of Cocolin?

Official regulatory reviews of clinical trials have noted that research findings regarding the magnitude of the drug’s effect have been mixed. The overall evidence is limited and mixed, leading to general uncertainty regarding its effectiveness and consistency.


Q: Is Cocolin indicated for use in people with high blood sugar?

No. The official regulatory indications for this medication are solely for the temporary relief of dry cough. It is not indicated for the management or treatment of high blood sugar, diabetes, or any related conditions.


Q: Are there any known effects of Cocolin on blood pressure?

The medication is not typically known to affect blood pressure when taken as directed for cough relief. However, high blood pressure (hypertension) is a documented symptom associated with Serotonin Syndrome and high-dose exposure.


Q: Are weight changes a known side effect of Cocolin?

Weight changes are not listed among the commonly documented or officially classified side effects in regulatory documents for the single-ingredient formulation.


Q: Is it normal to have mild headaches after starting Cocolin?

Headaches are not specifically listed among the common or officially classified side effects of the single-ingredient formulation in regulatory documents. If headaches occur, the patient information leaflet provides further context.


Q: Is Cocolin's purpose different in [Country A] compared to [Country B]?

Regulatory documents and international drug information databases classify the medication's main purpose—as an antitussive or cough suppressant—consistently across different territories.


Q: Are there any known interactions between Cocolin and common anxiety medications?

Yes, there are documented interactions. The medication has interactions with other Central Nervous System (CNS) depressants and with serotonergic agents (such as SSRIs and SNRIs), which are frequently used to treat anxiety. These combinations can increase the risk of serious adverse effects.

How should Cocolin be stored and disposed of?

How to Store and Dispose of Cocolin

All storage and disposal procedures for Cocolin (Dextromethorphan Hydrobromide) are strictly mandated by official regulatory documentation to maintain stability and ensure safety.

Storage Requirements

Cocolin must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and excess moisture, and specific liquid formulations must not be refrigerated. The product must be kept in its original, tightly closed container.

Crucially, Cocolin must be stored out of the sight and reach of children to prevent accidental ingestion, often requiring it to be stored locked up.

Disposal Instructions

Do not use the medicine after its printed expiry date. Disposal of unused product should follow official regulated procedures. The preferred method is using a local drug take-back location. Alternatively, for household disposal, the medicine must be mixed with an undesirable substance (e.g., dirt) in a sealed bag and placed in the trash. Medicines must not be thrown away via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cocolin found in:

A-Z Index: